An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.

NCT Number	NCT07527832
Lead Sponsor	Pfizer
Conditions	Colorectal Cancer
Enrollment	1,000 participants
Start Date	2026-04-20
Primary Completion	2026-05-27 (estimated)
Study Completion	2026-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-06-03